Biodegradable Drug Eluting Stents Market By material ( Metallic Alloy Stents, Polymeric Stents),  Application (Coronary Artery Disease, Peripheral Artery Disease), end-user,(Hospitals ardiac Centers) Geography (North America, Latin America, Europe, Asia Pacific and Middle East and Africa)

 

Biodegradable Drug Eluting Stents Market size was valued at USD x billion in 2021, growing at a CAGR of 5.3% from 2023-28. Drug-eluting stents are peripheral or coronary stents placed into narrowed peripheral or coronary arteries that slowly release the drug to block cell proliferation. Generally, these devices are made up of metal and remain permanently or removed through further surgery. Metal stents present drawbacks such as the predisposition to late stent thrombosis, impairment of imaging with multislice CT, hindrance of surgical revascularization. Biodegradable drug-eluting stents are made up of material that dissolves or absorbed in the body, these are temporary, and no need for further surgery to removal of the stent. These are also called as bioresorbable stents or naturally- dissolving stents. In October 2015, Boston Scientific Corporation received U.S. Food and Drug Administration (FDA) approval for the synergy bioabsorbable Polymer Drug-Eluting Stent System (BP-DES) for the treatment of coronary artery disease. Risk of complications in use and lower awareness about biodegradable stents among healthcare professionals in developing and developed regions are expected to hamper the growth of Biodegradable Drug Eluting Stents Market over the forecast period.